What Does Wall Street Think About Rigel Pharmaceuticals (RIGL)?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with total revenue for the quarter reaching approximately $101.7 million.

This included net product sales of $58.9 million and contract revenues from collaborations of $42.7 million. The company also generated $59.6 million in net income.

Following the results, Jefferies analyst Eun Yang maintained a Hold rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on August 6, setting a price target of $23.00.

However, the same day, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and set a $57.00 price target.

In another report released the same day, Citi also maintained a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and set a $67.00 price target.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.